Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 147

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 7
Chunk 147
---
, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical development, process development, manufacturing, and clinical development activities. 

The following table summarizes our research and development costs: 

    Year EndedDecember 31,

    2024

    2023

    (in thousands)

    Discovery costs

    Direct external costs
     
    $
    5,293

    $
    7,717

    Laboratory supplies and research materials

    3,357

    3,881

    Personnel related costs

    10,833

    11,710

    Facilities related costs

    1,640

    1,523

    Other costs

    3,366

    3,913

    24,489

    28,744

    Development costs

    Direct external costs

    Camonsertib program

    14,321

    23,420

    Lunresertib program

    29,071

    29,848

    RP-1664 program

    6,937

    6,337

    RP-3467 and Polθ program

    4,878

    6,500

    Personnel related costs

    34,478

    34,187

    Facilities related costs

    898

    867

    Other costs

    5,043

    5,154

    Debiopharm development cost reimbursement

    (3,242
    )

    —

    92,384

    106,313

    R&D tax credits

    (932
    )

    (1,464
    )

    Total research and development costs
     
    $
    115,941

    $
    133,593

The successful development of our product candidates is highly uncertain. We expect our research and development expenses to decrease in the short term as a result of the cost savings initiatives we implemented in connection with strategic reprioritization activities implemented in August 2024 and January 2025. We cannot determine with certainty the timing of initiation, the duration, or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of